Bavarian Biotech Report 2011/2012 (7MB) - Bio M

nexttec GmbHBIOTECH DNA/PROTEIN ANALYTICSContact:Prof. Dr. Gottfried BremThalmannsdorf 25D-86567 HilgertshausenPhone: +49 (0) 214 869-1516Fax: +49 (0) 214 869-1528E-Mail: service@nexttec.bizInternet: www.nexttec.bizThe nexttec 1-Step technology is a reversal of the usual, known DNA purificationsystems on a silica or magnetic bead base. Proteins, detergents andlow molecular weight compounds are retained by the nexttec sorbent.DNA passes through the nexttec cleanColumn during a short, one-steppurification procedure (4 minutes).The obtained DNA is suitable for all commonenzymatic reactions (restriction digests, real-time PCR, PCR, genotypingetc.).NIGU Chemie GmbHPHARMA & CHEMICAL INDUSTRYContact:Dr. Frank FleischerBeuthener Str. 2D-84478 WaldkraiburgPhone: +49 (0) 8638 962-0Fax: +49 (0) 8638 962-287E-Mail: info@nigu.deInternet: www.nigu.deNigu offers a full range of high-purity guanidine salts for biotechnologicalapplications, which meet the supreme quality standards set by the biopharmaceuticalindustry. The product group includes several grades of guanidinehydrochloride for separation and purification of recombinant proteins andantibodies. Guanidine thiocyanate for nucleic acid based diagnostics isanother integral part of the portfolio. A typical example is to provide guanidine-saltsand recycling of used solutions as a complete package to the biopharmaceuticalindustry.Contact:Martin BischofZielstattstr. 40D-81379 MünchenPhone: +49 (0) 89 7877-0Fax: +49 (0) 89 7877-250E-Mail:communications.munich_de@novartis.comInternet: www.novartis-consumerhealth.deNovartis Consumer Health GmbHPHARMA & CHEMICAL INDUSTRYNovartis Consumer Health, located in Munich, merchandises and distributesOTC and prescription drugs for self-medication.Novartis provides innovative healthcare solutions that address the evolvingneeds of patients and societies. Headquartered in Basel, Switzerland,Novartis offers a diversified portfolio to best meet these needs: innovativemedicines, eye care, cost-saving generic pharmaceuticals, preventive vaccinesand diagnostic tools, over-the-counter and animal health products.Novartis is the only global company with leading positions in these areas. In2011, the Group's continuing operations achieved net sales of USD 58.6billion, while approximately USD 9.6 billion (USD 9.2 billion excludingimpairment and amortization charges) was invested in R&D throughout theGroup. Novartis Group companies employ approximately 124,000 full-timeequivalentassociates and operate in more than 140 countries around theworld. For more information, please visit www.novartis.com.94